Brief: Monopar Receives Clearance To Proceed With First-In-Human Phase 1 Trial Of MNPR-101-ZR
20/02/2024 14:33
Feb 20 (Reuters) - Monopar Therapeutics Inc MNPR.O :
* MONOPAR RECEIVES CLEARANCE TO PROCEED WITH FIRST-IN-HUMAN
PHASE
1 TRIAL OF NOVEL RADIOPHARMACEUTICAL MNPR-101-ZR IN ADVANCED
CANCERS
Source text for Eikon: ID:nGNX1Jps5V
Further company coverage: MNPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monopar Therapeutics
See all newsBrief: Monopar Appoints Jeffrey D. Kent, M.D., As Executive Vice President, Head Of Medical Affairs Announces Two Alxn1840 Presentations At Aasld – The Liver Meeting 2026
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Monopar Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Monopar Therapeutics Inc. expected to post a loss of 62 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Alphabet, IBM, Tesla